Diabetes Education News

In this video, David Nathan, MD, discusses the side effects of weight loss caused by type 2 diabetes medications and the risks of prescribing these medications to patients without diabetes.

Hepatic steatosis was prevalent among 52% of adults with or without type 2 diabetes and no known history of metabolic dysfunction-associated steatotic liver disease, according to findings published in Obesity.

Follow-up albuminuria testing can be an important step in kidney care following initial abnormal results from a urine protein dipstick test, according to an analysis of health records.

Shortages of tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, have been resolved, the FDA announced.

In this video, David Nathan, MD, discusses the various treatment options for patients with diabetes.

One of many challenges parents face when their child is diagnosed with diabetes is how the condition will be managed in school, particularly if the child is using a diabetes device.

Decreases in body weight and HbA1c induced by GLP-1 receptor agonists and other diabetes drugs can reduce the risk for cardiometabolic complications for adults newly diagnosed with type 2 diabetes, researchers reported.

The FDA has lifted a clinical hold on two trials assessing an investigational treatment for people with type 1 and type 2 diabetes, Biomea Fusion announced.

A recently proposed U.S. Senate bill aims to crack down on social media influencers and others online who make misleading comments about pharmaceutical drugs.

Replacing ultraprocessed foods with lesser or nonprocessed options may decrease the risk of developing type 2 diabetes, results from a prospective cohort analysis in the Lancet Regional Health Europe showed.